|
National Stock Number(NSN): 6505-01-434-0307 (6505014340307, 014340307)
| NIIN: |
01-434-0307 |
Item Name: |
CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES |
INC: |
42664
|
| FSC: |
6505
|
Assignment Date: |
Jul-17-1996 |
CRIT: |
X |
IIG: |
42664 |
| ISC: |
2 |
Date Standardized: |
Jul-17-1996 |
HMIC: |
P |
DODIC: |
|
| NSC: |
4 |
Cancellation Date: |
Nov-01-2000 |
PMIC: |
A |
FIIG: |
A510U0 |
| ESD: |
|
Schedule B: |
|
DEMIL: |
A |
DEMIL INT: |
|
| TIIC: |
4 |
Originator: |
KX |
ADPEC: |
|
RPDMRC: |
3 |
| Part Number |
CAGE |
Company |
Status |
RN CC |
RN VC |
DAC |
RN AAC |
RN FC |
RN SC |
RN JC |
SADC |
HCC |
MSDS |
|
96-0423 |
89875
|
DEFENSE LOGISTICS AGENCY DIRECTORATE OF MEDICAL MATERIEL DEFENSE SUPPLY CENTER PHILADELPHIA |
H |
5 |
1 |
4 |
ZZ |
|
|
|
|
|
|
|
DECONAMINE SR |
0UW09
|
KENWOOD LABORATORIES BRADLEY PHARM INC DIV |
H |
5 |
1 |
4 |
ZZ |
|
|
|
|
|
|
|
NDC00482-0181-70 |
0UW09
|
KENWOOD LABORATORIES BRADLEY PHARM INC DIV |
H |
3 |
2 |
4 |
ZZ |
|
|
|
|
|
|
| MOEC |
SOS |
A A C |
R C |
S L C |
CIIC |
U P Q |
U S C |
Unit Price |
UI |
UICF |
MCD |
Action Date |
C/H |
| DA |
S9M |
L |
|
Q |
U |
1 |
A |
$85.50 |
BT |
|
C2201X- |
Sep-01-1996 |
H |
| DF |
JDC |
L |
|
Q |
U |
1 |
F |
$85.50 |
BT |
|
------- |
Jul-01-1996 |
H |
| DN |
JDC |
L |
|
Q |
U |
1 |
N |
$85.50 |
BT |
|
9L----- |
Jul-01-1996 |
H |
| DS |
JDC |
L |
|
Q |
U |
1 |
D |
$85.50 |
BT |
|
------- |
Jul-01-1996 |
H |
| MOEC |
PC |
Phrase |
QPA |
UOM |
OOU |
JTC |
| DF |
K |
U/I CONTAINS 1000EA |
000 |
|
|
|
| DN |
K |
U/I CONTAINS 1000EA |
000 |
|
|
|
| DS |
K |
U/I CONTAINS 1000EA |
000 |
|
|
|
Technical Characteristics Information
| MRC |
Requirement Statement |
Reply Statement |
| FEAT |
SPECIAL FEATURES |
8 MG CHLORPHENIRAMINE MALEATE, 120 MG PSEUDOEPHEDRINE HYDROCHLORIDE; 1000 CAPSULES PER BT |
| MOE Rule |
Former MOER |
Effective |
AMC |
AMSC |
IMC |
IMCA |
Collaborators |
Receivers |
| A111 |
|
Apr-28-2000 |
3 |
H |
|
|
|
|
| FSKX |
|
Apr-28-2000 |
3 |
H |
|
|
|
|
| N9LM |
|
Apr-28-2000 |
3 |
H |
|
|
|
|
|